Author:
Lu Huaiwu,Liu Yunyun,Wang Dongyan,Wang Lijuan,Zhou Hui,Xu Guocai,Xie Lingling,Wu Miaofang,Lin Zhongqiu,Yu Yuefei,Li Guorong
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Kigawa J. New strategy for overcoming resistance to chemotherapy of ovarian cancer. Yonago Acta Med. 2013;56:43–50.
2. Stewart LA, Guthrie D, Parmar MK, Williams CJ. Chemotherapy in advanced ovarian cancer. BMJ. 1992;304:119.
3. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.
4. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.
5. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57:5272–6.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献